Breaking News, Trials & Filings

Trials & Filings in Brief: Nov. 22, 2013

Bayer, Biogen Idec, DelMar, Janssen, J&J, Pfizer, Regeneron, Sanofi, Threshold

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I DelMar presents dose-escalation interim results . . . read more No dose-limiting toxicity in Threshold study . . . read more Phase III Sanofi, Regeneron RA drug shows effectiveness . . . read more Filings Biogen idec drug gets protection in EU . . . read more Eylea approved in Japan . . . read more J&J diabetes treatment approved in EU . . . read more Xalkori gets full approval . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters